
Overview
Milton Essex is a med-tech company specializing in allergy diagnostics, offering products such as the SkinSENS™ system and the Allergoscope program. The company conducts research utilizing artificial intelligence, optoelectronics, and thermodynamics to develop innovative medical systems. Additionally, it focuses on creating new medical procedures and strong partnerships to revolutionize healthcare.
Financials
Revenue history (in k)
Financial insight
- The statement flags a going concern risk. Istnieją okoliczności wskazujące na zagrożenie kontynuowania działalności z uwagi na fakt długotrwale utrzymującej się straty oraz ze względu na brak płynności finansowej.
Filing timeliness
5 of 6 financial statements were filed late (the longest delay 155 days for 2023). All were audited by a statutory auditor.
- 202515/07/2026
- 202421/10/2025
- 202317/12/2024
- 202220/10/2023
- 202104/10/2022
- 202005/11/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Stock quotes
- Open
- PLN 0.39
- High
- PLN 0.39
- Low
- PLN 0.32
- Volume
- 218.71K
- Avg. vol.
- 71.75K
- Market cap
- PLN 26.29M
- P/E ratio
- –
- EPS
- -PLN 0.02
- Shares outstanding
- 75.11M
- 52-week
- PLN 0.32 – 0.47
- Dividend yield
- –
- Dividend
- –
- Ex dividend date
- –
- ISIN
- PLMLTNE00013
- Exchange
- NewConnect
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | USD 0.00 | USD -4.18 | – |
| Q1 2026 | USD 0.00 | USD -10.98 | – |
| Q4 2025 | USD 0.00 | – | – |
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
News
Extensive meeting programme of Milton Essex Group representatives at this year's MSPO'26
Periodic report (EBI): Report for 2Q 2026
Current report (ESPI) 20/2026: launch of the first stage of the clinical trials project
Current report (ESPI) 20/2026: launch of the first stage of the clinical trials project
Current report (EBI) 16/2026: appointment of the Supervisory Board
Industry
Offer
- Allergy diagnostic system
- Allergic skin tests
- Multispectral imaging system
- Temperature measurement device
- Skin imaging device
Websites
- miltonessex.euMILTON ESSEX – diagnostyka alergii i med-tech AIWordPress 7.1Yoast SEOLLiteSpeed
Trademarks
The company holds 4 active trademarks registered with the Polish Patent Office. 4 marks have expired or were not registered. The first mark was filed in 2014.
| Mark | Protected until | |
|---|---|---|
| SkinSense | Aug 28, 2030 | |
| FACE-COV | Jun 19, 2030 | |
| InfraSkin | Dec 20, 2028 | |
| S InfraScan | Nov 16, 2028 | |
| SkinSensic | – |
Authorized Representatives
Manner of representation
President of the Management Board acting independently, or two members of the management board acting jointly.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Subsidiaries
| Name | Share value | Stake | ||
|---|---|---|---|---|
Sanford Biotech sp. z o.o. | 2,079.96 USD | 100% | ||
Milton Medical Ai P.S.A. | 1,350.62 USD | 100% |
Bank accounts
Registered as a VAT taxpayer on 2015-09-22.
41 1090 1870 0000 0001 6726 7534
Debt
No entries in the National Debtors Register (KRZ).
Real estate
| Type | Amount |
|---|---|
Buildings and premises | PLN 2,891PLN 2,891 |
MSiG notices
| Publication date | Event | |
|---|---|---|
| Nov 17, 2025 | List of claims | |
| Jun 30, 2020 | Shareholders' meeting convened |
Public aid
11 public aid cases recorded, with a total value of $4,712,432.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Nov 13, 2020 | Aid for research and development projects: industrial research | $1.2M$1,229,870 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Nov 13, 2020 | Aid for research and development projects: experimental development | $528.8K$528,809 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Sep 21, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $3,653$3,653 | Prezes Zakładu Ubezpieczeń Społecznych |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2020-06-07 | FACE-COV™ – a system solution for automated monitoring of public places using thermographic imaging and detection of SARS-COV2 infection markers with artificial intelligence, including a biometric identification option (digital tagging), meeting medical device standards. | $1.8M$1,784,321 | Operational Programme Smart Growth | |
| 2018-07-01 | Obtaining international patent protection for 1 invention in the MedTech field. | $54,395$54,395 | Operational Programme Smart Growth | |
| 2015-09-01 | FIRIMAS – A solution for functional imaging of cutaneous allergic responses in the infrared | $918.6K$918,612 | Operational Programme Smart Growth |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Oasis Diagnostics S.A. | $282,613.94 | oasis-diagnostics.com | ||
| Envcheck sp. z o.o. | $263,693.85 | envcheck.com | ||
| Invinets sp. z o.o. | $194,320.82 | invinets.pl | ||
| Irtsys sp. z o.o. | $181,210.54 | irtsys.pl | ||
| Radialtec Poland sp. z o.o. | $165,016.64 | radialtec.net | ||
| Instella sp. z o.o. | $45,239.92 | instella.pl | ||
| Smart Labs sp. z o.o. | $32,047.41 | smart-labs.pl | ||
| Insway Technology sp. z o.o. | $28,382.19 | insway.pl | ||
| Grupa Psychotronics sp. z o.o. | $27,307.51 | psychotronics.pl | ||
| Smartmedics sp. z o.o. | $18,638.38 | smartmedics.pl |
Change history
| Date | Event | |
|---|---|---|
| 2026-06-12 | Share capital increase (1,551,767.00 PLN → 7,511,202.60 PLN) | |
| 2024-04-16 | Address change (Ul. Jana Pawła Woronicza 31/348, 02-640, Warszawa → Ul. Żołny 42a, 02-815, Warszawa) | |
| 2020-08-05 | Share capital increase (1,276,767.00 PLN → 1,551,767.00 PLN) | |
| 2019-06-14 | Share capital increase (1,136,100.00 PLN → 1,276,767.00 PLN) | |
| 2018-04-25 | Share capital increase (1,040,100.00 PLN → 1,136,100.00 PLN) |
FAQ
Last updated: 2026-07-30